RxDoctor Payments Data

Werther Marciales, MD

Internal Medicine · Bradenton, FLNPI 1619974839

Payments from drug & device makers

$869in general payments, 2019–2025

Across 21 payments — averaging $41.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nuwellis, Inc.$394
  • Johnson & Johnson$179
  • Abbott$137
  • Sunovion Pharmaceuticals Inc.$40
  • Cipher Pharmaceuticals US LLC$28
  • Novo Nordisk$19
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$73685%
  • Education$13315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nuwellis, Inc.3$394
Johnson & Johnson5$179
Abbott2$137
Sunovion Pharmaceuticals Inc.4$40
Cipher Pharmaceuticals US LLC1$28
Novo Nordisk1$19
GSK1$17
Pfizer1$15
Insmed, Inc.1$15
Astellas Pharma US Inc1$14
Amgen1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$869 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$282,138
Medicare patients
702
Services billed
2,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban537$160,519
XifaxanRifaximin94$140,984
NuplazidPimavanserin Tartrate14$33,231
AptiomEslicarbazepine Acetate26$32,157
Divalproex Sodium351$29,064
JardianceEmpagliflozin64$20,436
VemlidyTenofovir Alafenamide11$16,668
RexultiBrexpiprazole20$14,191
Daptomycin13$13,972
Sevelamer Hcl18$12,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$11,990
Combivent RespimatIpratropium/Albuterol Sulfate20$10,420
Gabapentin316$10,176
XareltoRivaroxaban30$10,164
Levetiracetam149$9,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$160,519537 claims
Sunovion Pharmaceuticals Inc.Aptiom$40$32,15726 claims
GSKTrelegy Ellipta$17$11,99032 claims
Johnson & JohnsonXarelto$179$10,16430 claims
Novo NordiskTresiba$19$4,22712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →